Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the goal of developing novel gene therapy approaches to cure this and many other types of genetic diseases.
Tevard (tā-vərd)
reversing Dravet…
Setting out to find revolutionary approaches to cure patients with Dravet, Harvey, together with the research labs of Professors Jeff Coller and Chris Ahern, invented two unique tRNA-based platforms that could cure not only Dravet, but many other rare diseases caused by having only one healthy copy of a gene leads to insufficient protein productionhaploinsufficiency and/or substitution of a single nucleotide produces a premature stop codon, leading to truncated, non-functional proteinsnonsense mutations.
Dravet syndrome is a rare and severe form of epilepsy that affects approximately 1 in 16,000 individuals. In 85% of cases, Dravet is caused by a loss-of-function mutation in one copy (haploinsufficiency) of the SCN1A gene. Over 20% of Dravet causing mutations are premature stop codons, causing production of a nonfunctional protein fragment.
Due to its large size, the SCNIA gene cannot be delivered by common viral vectors. What’s more, over-expressing SCN1A can have deleterious effects. Therefore, Dravet—like many other genetic diseases—is not amenable to traditional gene therapy approaches.
We have developed two unique tRNA-based therapies with the potential to provide durable cures for many rare diseases.
For diseases caused by nonsense mutations. By using a viral vector to express a patented tRNA in targeted cells, we insert the normal amino acid at the site of the premature stop codon, generating a normal functional protein. Because many diseases share same premature stop codon, the same Suppressor tRNA can treat multiple diseases.
For diseases caused by haploinsufficiency. By using a viral vector to overexpress a unique combination of endogenous tRNAs in targeted cells, we increase the amount of protein produced by the wild-type (functional) copy of the specific gene to its normal level by increasing the stability and thus the half-life of its mRNA.
Our lead CNS indication is Dravet syndrome, for which we are currently pursuing a dual approach: using Enhancer tRNAs Stabilization to increase expression of the healthy copy of SCN1A and using Suppressor tRNAs to allow production of full-length protein off the faulty copy of the gene.
Closely following our Dravet program , we are developing cures for other genetic epilepsies and CNS indications.
Beyond CNS we are also pursuing non-CNS indications caused by haploinsufficiency and/or nonsense mutations.
An estimated 300 to 1000 diseases are caused by haploinsufficiency, where a single functional copy of a gene is insufficient for normal function, and 1800 diseases are the result of nonsense mutations, in total, affecting millions of patients world-wide.
Tevard has assembled a team of scientific, clinical, and industry leaders to drive tRNA therapies to patients in a timeframe that matters.
Co-Founder, Chair of the SAB, and Board Member
Co-Founder and Chairman of the Board
Scientific Co-Founder, Scientific Advisor
Co-Founder, President and CEO, Board Member
Chief Scientific Officer
Scientific Advisor, Board Member
Scientific Advisor
Scientific Advisor
Board Member
Scientific Advisor
Board Member
Board Member
Board Member
Scientific Advisor
Scientific Advisor
Scientific Advisor
Scientific Advisor, Board Observer
VP of Finance
VP of Development Operations
Associate Director Research
Senior Research Scientist, In Vivo
Advisor
Board Observer
Scientific Advisor
Scientific Advisor
Research Associate II
Senior Associate Scientist II
Research Scientist
Senior Research Scientist
Associate Director of Lab Operations
Senior Research Associate II, Molecular Biology
Senior Scientist
Research Associate
Associate Director, PD and CMC
Senior Research Scientist
Senior Research Associate
Senior Research Scientist, RNA Biology
Principal scientist
Research Associate
Research Associate, in vivo Pharmacology
Tevard Biosciences, Inc., the pioneer of tRNA-based therapies and other mRNA-modulating treatments for genetic diseases, announced today that it has appointed Dr. Gregory Robinson as Chief Scientific Officer. Dr. Robinson brings extensive leadership experience with research and clinical development. “Dr. Robinson has a long track record of success in translating innovative science into new medicines […]
Tevard Biosciences, Inc., the pioneer of tRNA-based therapies for severe genetic diseases, today announced a four-year global research collaboration with Vertex Pharmaceuticals Incorporated aimed at creating new tRNA-based therapies for patients with Duchenne muscular dystrophy (DMD) caused by nonsense mutations with options to expand into additional muscular dystrophies and a second indication. The agreement provides […]
At Tevard we are looking for highly-qualified and passionate professionals to join our team. As a member of our team you will become a part of our mission to develop novel tRNA-based therapies to transform patients’ and families’ lives.
Research Associate – in vivo Pharmacology
Download PDF.
Research Associate – mRNA Biology
Download PDF.
Computational Biologist and Machine Learning
Download PDF.